Cargando…

Proton Pump Inhibitors Inhibit PHOSPHO1 Activity and Matrix Mineralisation In Vitro

Proton pump inhibitors (PPIs) have been associated with an increased risk of fragility fractures in pharmaco-epidemiological studies. The mechanism is unclear, but it has been speculated that by neutralising gastric acid, they may reduce intestinal calcium absorption, causing secondary hyperparathyr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Staines, Katherine A., Myers, Katherine, Little, Kirsty, Ralston, Stuart H., Farquharson, Colin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531085/ https://www.ncbi.nlm.nih.gov/pubmed/34213594 http://dx.doi.org/10.1007/s00223-021-00882-9

Ejemplares similares

The Expression of PHOSPHO1, nSMase2 and TNAP is Coordinately Regulated by Continuous PTH Exposure in Mineralising Osteoblast Cultures
por: Houston, D. A., et al.
Publicado: (2016)

How To Build a Bone: PHOSPHO1, Biomineralization, and Beyond
por: Dillon, Scott, et al.
Publicado: (2019)

Chondrogenic ATDC5 cells: An optimised model for rapid and physiological matrix mineralisation
por: NEWTON, P.T., et al.
Publicado: (2012)

Increased PHOSPHO1 expression mediates cortical bone mineral density in renal osteodystrophy
por: Hsu, Shun-Neng, et al.
Publicado: (2022)

E11/Podoplanin Protein Stabilization Through Inhibition of the Proteasome Promotes Osteocyte Differentiation in Murine in Vitro Models
por: Staines, Katherine A., et al.
Publicado: (2015)

Kinetic Analysis of Substrate Utilization by Native and TNAP-, NPP1-, or PHOSPHO1-Deficient Matrix Vesicles
por: Ciancaglini, Pietro, et al.
Publicado: (2010)

Azathioprine Has a Deleterious Effect on the Bone Health of Mice with DSS-Induced Inflammatory Bowel Disease
por: Morgan, Stephanie, et al.
Publicado: (2019)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Proton Pump Inhibitors and Gastritis
por: Suzuki, Masayuki, et al.
Publicado: (2008)

Proton pump inhibitors and gastroenteritis
por: Hassing, Robert-Jan, et al.
Publicado: (2016)

Deprescribing proton pump inhibitors
por: Teh, Kim Jun Kevin, et al.
Publicado: (2023)

Intravesicular Phosphatase PHOSPHO1 Function in Enamel Mineralization and Prism Formation
por: Pandya, Mirali, et al.
Publicado: (2017)

Human osteoblasts within soft peptide hydrogels promote mineralisation in vitro
por: Castillo Diaz, Luis A, et al.
Publicado: (2014)

In vitro mineralisation of grafted ePTFE membranes carrying carboxylate groups
por: Hidzir, Norsyahidah Mohd, et al.
Publicado: (2017)

DP2, a Carbohydrate Derivative, Enhances In Vitro Osteoblast Mineralisation
por: Ballout, Nissrine, et al.
Publicado: (2023)

Inhibition of Tryptophan Hydroxylases and Monoamine Oxidase-A by the Proton Pump Inhibitor, Omeprazole—In Vitro and In Vivo Investigations
por: Betari, Nibal, et al.
Publicado: (2020)

Meniscal mineralisation in little spotted cats
por: Rahal, Sheila C, et al.
Publicado: (2013)

Quantifying the efficiency of Hydroxyapatite Mineralising Peptides
por: Plowright, Robyn, et al.
Publicado: (2017)

Evaluation of proton pump inhibitor administration in hospitalized dogs in a tertiary referral hospital
por: Duxbury, Samantha, et al.
Publicado: (2022)

Progress with proton pump inhibition.
por: Bell, N. J., et al.
Publicado: (1992)

Extracellular ATP Released by Osteoblasts Is A Key Local Inhibitor of Bone Mineralisation
por: Orriss, Isabel R., et al.
Publicado: (2013)

Proton Pump Inhibitors and the Risk of Adverse Cardiac Events
por: Juurlink, David N., et al.
Publicado: (2013)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Proton pump inhibitors and hypomagnesemia monitoring
por: Lemon, Thomas I
Publicado: (2013)

Use and overuse of proton pump inhibitors
por: Staiano, Annamaria, et al.
Publicado: (2015)

Symptomatic hypomagnesemia and proton pump inhibitors
por: Tin, Sim Sai, et al.
Publicado: (2014)

2389. Assessing the Time Course of Proton Pump Inhibitor Use and Clostridioides difficile Infection
por: Panagos, Katherine, et al.
Publicado: (2019)

Culture of Murine Embryonic Metatarsals: A Physiological Model of Endochondral Ossification
por: Houston, Dean A., et al.
Publicado: (2016)

The role of accelerated growth plate fusion in the absence of SOCS2 on osteoarthritis vulnerability
por: Samvelyan, Hasmik Jasmine, et al.
Publicado: (2022)

Fibroblast growth factor 23 and bone mineralisation
por: Guo, Yu-Chen, et al.
Publicado: (2015)

Effects of E’Jiao on Skeletal Mineralisation, Osteocyte and WNT Signalling Inhibitors in Ovariectomised Rats
por: Chin, Kok-Yong, et al.
Publicado: (2023)

Risk of Pyogenic Liver Abscess in Proton Pump Inhibitor Users: New Inventory of Proton Pump Inhibitor Induced Complications?
por: Bang, Ki Bae
Publicado: (2021)

Citrate Supplementation Restores the Impaired Mineralisation Resulting from the Acidic Microenvironment: An In Vitro Study
por: Perut, Francesca, et al.
Publicado: (2020)

Proton Pump Inhibitors Inhibit Metformin Uptake by Organic Cation Transporters (OCTs)
por: Nies, Anne T., et al.
Publicado: (2011)

Offsetting anthropogenic carbon emissions from biomass waste and mineralised carbon dioxide
por: Tripathi, Nimisha, et al.
Publicado: (2020)

Management of laryngopharyngeal reflux with proton pump inhibitors
por: Reimer, Christina, et al.
Publicado: (2008)

Proton Pump Inhibitor Induced Depigmentation in Vitiligo
por: Holla, Anantha Prasad, et al.
Publicado: (2011)

Proton pump inhibitor-induced hypomagnesemic hypoparathyroidism
por: Swaminathan, Krishnan
Publicado: (2015)

Proton pump inhibitors: A balanced view
por: Ramakrishna, B.S.
Publicado: (2015)

Proton Pump Inhibitors: The Culprit for Barrett’s Esophagus?
por: Alsalahi, Omran, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fb38gd3ni13vk72c2v12i5ujuj